Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology-Reference-Cited by-同舟云学术

Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

Published:2022-09 Issue:9 Volume:20 Page:1033-1062
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

Gerds Aaron T.¹,Gotlib Jason²,Ali Haris³,Bose Prithviraj⁴,Dunbar Andrew⁵,Elshoury Amro⁶,George Tracy I.⁷,Gundabolu Krishna⁸,Hexner Elizabeth⁹,Hobbs Gabriela S.¹⁰,Jain Tania¹¹,Jamieson Catriona¹²,Kaesberg Paul R.¹³,Kuykendall Andrew T.¹⁴,Madanat Yazan¹⁵,McMahon Brandon¹⁶,Mohan Sanjay R.¹⁷,Nadiminti Kalyan V.¹⁸,Oh Stephen¹⁹,Pardanani Animesh²⁰,Podoltsev Nikolai²¹,Rein Lindsay²²,Salit Rachel²³,Stein Brady L.²⁴,Talpaz Moshe²⁵,Vachhani Pankit²⁶,Wadleigh Martha²⁷,Wall Sarah²⁸,Ward Dawn C.²⁹,Bergman Mary Anne³⁰,Hochstetler Cindy³⁰

Affiliation:

1. 1Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

2. 2Stanford Cancer Institute;

3. 3City of Hope National Medical Center;

4. 4The University of Texas MD Anderson Cancer Center;

5. 5Memorial Sloan Kettering Cancer Center;

6. 6Roswell Park Comprehensive Cancer Center;

7. 7Huntsman Cancer Institute at the University of Utah;

8. 8Fred & Pamela Buffett Cancer Center;

9. 9Abramson Cancer Center at the University of Pennsylvania;

10. 10Massachusetts General Hospital Cancer Center;

11. 11The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

12. 12UC San Diego Moores Cancer Center;

13. 13UC Davis Comprehensive Cancer Center;

14. 14Moffitt Cancer Center;

15. 15UT Southwestern Simmons Comprehensive Cancer Center;

16. 16University of Colorado Cancer Center;

17. 17Vanderbilt-Ingram Cancer Center;

18. 18University of Wisconsin Carbone Cancer Center;

19. 19Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

20. 20Mayo Clinic Cancer Center;

21. 21Yale Cancer Center/Smilow Cancer Hospital;

22. 22Duke Cancer Institute;

23. 23Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

24. 24Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

25. 25University of Michigan Rogel Cancer Center;

26. 26O'Neal Comprehensive Cancer Center at UAB;

27. 27Dana-Farber/Brigham and Women’s Cancer Center;

28. 28The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

29. 29UCLA Jonsson Comprehensive Cancer Center; and

30. 30National Comprehensive Cancer Network.

Abstract

The classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPN) consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a heterogeneous group of clonal blood disorders characterized by an overproduction of blood cells. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for MPN were developed as a result of meetings convened by a multidisciplinary panel with expertise in MPN, with the goal of providing recommendations for the management of MPN in adults. The Guidelines include recommendations for the diagnostic workup, risk stratification, treatment, and supportive care strategies for the management of myelofibrosis, polycythemia vera, and essential thrombocythemia. Assessment of symptoms at baseline and monitoring of symptom status during the course of treatment is recommended for all patients. This article focuses on the recommendations as outlined in the NCCN Guidelines for the diagnosis of MPN and the risk stratification, management, and supportive care relevant to MF.

Publisher

Harborside Press, LLC

Subject

Oncology

Link

https://jnccn.org/downloadpdf/journals/jnccn/20/9/article-p1033.xml

Reference490 articles.

1. Targeted sequencing improves DIPSS-Plus prognostic scoring in myelofibrosis patients undergoing allogeneic transplantation;Stevens;Biol Blood Marrow Transplant,2020

2. Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study;Sørensen;Haematologica,2020

3. Thalidomide treatment in myelofibrosis with myeloid metaplasia;Elliott;Br J Haematol,2002

4. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report;Tefferi;Blood,2013

5. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis;Masarova;Leuk Res,2017

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A germline JAK2 exon12 mutation and a late somatic CALR mutation in a patient with essential thrombocythemia;Frontiers in Oncology;2024-01-04

2. Discontinuation Syndrome With JAK2 Selective Agents: Case Presentation and Mechanistic Insights;JCO Precision Oncology;2024-01

3. Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases;Pharmacological Research;2024-01

4. Ph-Negative Chronic Myeloproliferative Neoplasms;Reference Module in Biomedical Sciences;2024

5. SOHO State of the Art Updates and Next Questions | Diagnosis, Outcomes, and Management of Prefibrotic Myelofibrosis;Clinical Lymphoma Myeloma and Leukemia;2024-01